Newsroom

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’...

read more +
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’...

read more +
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucoma. These 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population

read more +
Sight Sciences Reports First Quarter 2022 Financial Results

Sight Sciences Reports First Quarter 2022 Financial Results   May 10, 2022 PDF Version   MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an...

read more +
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

MENLO PARK, Calif., April 29, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’...

read more +
Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

PDF Version MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’...

read more +
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021.

read more +
Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject® in lowering intraocular pressure (IOP) as a standalone treatment option without concomitant cataract surgery.

read more +